As for CRISPR technology, genome-wide CRISPR screens have served for the identification of oxidative stress-responsive genes in CRC such as Galectin-2 (Gal2) which has a tumor-suppressive role in this cancer [161]. This evidence concerns the gene LGALS2 and colorectal carcinoma.